References
- Beer TM , El-GeneidiM , EilersKM. Docetaxel (Taxotere®) in the treatment of prostate cancer. Expert Rev. Anticancer Ther.3, 261–268 (2003).
- Reddy LH , BazileD. Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics. Adv. Drug. Deliv. Rev.71, 34–57 (2014).
- Hart M , AcottS. Physical and chemical stability of Taxotere® (docetaxel) one-vial (20 mg/ml) infusion solution following refrigerated storage. Ecancermedicalscience4, 202 (2010).
- Rao BM , ChakrabortyA , SrinivasuMKet al. A stability-indicating HPLC assay method for docetaxel. J. Pharm. Biomed. Anal.41, 676–681 (2006).
- Sonali , SinghRH , SharmaGet al. RGD-TPGS decorated theranostic liposomes for brain targeted delivery. Colloids Surf B Biointerfaces.147, 129–141 (2016).
- Kalepu S , NekkantiV. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm. Sin. B5, 442–453 (2015).
- Narvekar M , XueHY , EohJYet al. Nanocarrier for poorly water-soluble anticancer drugs—barriers of translation and solutions. AAPS PharmSciTech.15, 822–833 (2014).
- Blagosklonny MV . Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Cell Cycle3, 1033–1040 (2004).
- Sohail MF , RehmanM , SarwarHSet al. Advancements in the oral delivery of docetaxel: challenges, current state-of-the-art and future trends. Int. J. Nanomed.13, 3145–3161 (2018).
- Clarke SJ , RivoryLP. Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet.36, 99–114 (1999).
- Thiesen J , KrämerI. Physico-chemical stability of docetaxel premix solution and docetaxel infusion solutions in PVC bags and polyolefine containers. Pharm. World Sci.21, 137–141 (1999).
- Sonali , AgrawalP , SinghRPet al. Transferrin receptor-targeted vitamin E TPGS micelles for brain cancer therapy: preparation, characterization and brain distribution in rats. Drug Deliv.23, 1788–1798 (2016).
- Soga O , van NostrumCF , FensMet al. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. J. Control. Rel.103, 341–353 (2005).
- Kerwin BA . Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J. Pharm. Sci.97, 2924–2935 (2008).
- Khan TA , MahlerHC , KishoreRS. Key interactions of surfactants in therapeutic protein formulations: a review. Eur. J. Pharm. Biopharm.97, 60–67 (2015).
- Owens DE 3rd , PeppasNA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm.307, 93–102 (2006).
- Suk JS , XuQ , KimN , HanesJet al. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev.99, 28–51 (2016).
- Muthu MS , KulkarniSA , LiuY , FengSS. Development of docetaxel-loaded vitamin E TPGS micelles: formulation optimization, effects on brain cancer cells and biodistribution in rats. Nanomedicine7, 353–364 (2012).
- Muthu MS , MeiL , FengSS. Nanotheranostics: advanced nanomedicine for the integration of diagnosis and therapy. Nanomedicine9, 1277–1280 (2014).
- Viswanadh MK , MuthuMS. Targeted bioadhesive nanomedicine: an effective approach for synergistic drug delivery to cancers. Nanomedicine13, 1401–1403 (2018).